Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension

This study aims to evaluate the efficacy and safety of HRS-9563 in patients with mild to moderate hypertension, and to explore its appropriate dosage.

Inclusion Criteria: 1. The subject voluntarily signs the informed consent form. 2. Male or female, aged ≥ 18 years and ≤ 75 years; 3. Patients with mild to moderate hypertension; 4. At the Screening and Baseline periods, the mean sitting office systolic blood pressure is \> 130 mmHg, and the 24-hour mean systolic blood pressure assessed by ABPM at Screening is ≥ 130 mmHg and \< 160 mmHg. Exclusion Criteria: 1. Secondary hypertension; 2. Orthostatic hypotension; 3. Type 1 diabetes or poorly controlled type 2 diabetes; 4. Occurrence of any cardiovascular or cerebrovascular event within 6 months prior to screening; 5. Presence of uncontrolled severe arrhythmia within 6 months prior to screening; 6. Suspected allergy to the investigational drug or any of its components; 7. Other diseases requiring Renin-Angiotensin-Aldosterone System (RAAS) inhibitor therapy, besides hypertension; 8. Any blood biochemical indicator during screening or baseline did not meet the standards in the exclusion criteria; 9. Use of any medication affecting blood pressure within 4 weeks prior to screening, or planned use during the study period;